InterCure Ltd. (INCR)
USD 1.42
(-1.05%)
USD 1.42
(-1.05%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 786.61 Million ILS | -17.89% |
| 2022 | 958 Million ILS | 39.59% |
| 2021 | 686.32 Million ILS | 110.35% |
| 2020 | 326.27 Million ILS | 15.6% |
| 2019 | 282.23 Million ILS | 685.73% |
| 2018 | 35.92 Million ILS | 50.0% |
| 2017 | 23.94 Million ILS | -13.66% |
| 2016 | 27.73 Million ILS | 119.75% |
| 2015 | 12.62 Million ILS | 378.04% |
| 2014 | 2.64 Million ILS | -57.17% |
| 2013 | 6.16 Million ILS | -57.57% |
| 2012 | 14.52 Million ILS | 397.71% |
| 2011 | 2.91 Million ILS | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 740.88 Million ILS | 0.0% |
| 2024 Q1 | 740.88 Million ILS | -5.81% |
| 2023 Q3 | 786.61 Million ILS | -6.56% |
| 2023 Q2 | 841.84 Million ILS | -3.86% |
| 2023 FY | 786.61 Million ILS | -17.89% |
| 2023 Q1 | 875.67 Million USD | -8.59% |
| 2023 Q4 | 786.61 Million ILS | 0.0% |
| 2022 Q3 | 874.82 Million ILS | 10.31% |
| 2022 Q4 | 958 Million ILS | 9.51% |
| 2022 Q1 | 743.73 Million ILS | 8.37% |
| 2022 Q2 | 793.06 Million ILS | 6.63% |
| 2022 FY | 958 Million ILS | 39.59% |
| 2021 Q3 | 655.6 Million ILS | 11.41% |
| 2021 Q4 | 686.32 Million ILS | 4.69% |
| 2021 Q1 | 342.87 Million ILS | 5.09% |
| 2021 FY | 686.32 Million ILS | 110.35% |
| 2021 Q2 | 588.48 Million ILS | 71.63% |
| 2020 FY | 326.27 Million ILS | 15.6% |
| 2020 Q2 | 257.85 Million ILS | 7.16% |
| 2020 Q3 | 320.85 Million ILS | 24.43% |
| 2020 Q4 | 326.27 Million ILS | 1.69% |
| 2020 Q1 | 240.63 Million ILS | -14.74% |
| 2019 FY | 282.23 Million ILS | 685.73% |
| 2019 Q3 | 70.55 Million ILS | -75.93% |
| 2019 Q4 | 282.23 Million ILS | 300.0% |
| 2019 Q1 | 70.55 Million ILS | 96.43% |
| 2019 Q2 | 293.14 Million ILS | 315.46% |
| 2018 Q2 | 21.27 Million ILS | 0.22% |
| 2018 Q3 | 35.92 Million ILS | 68.8% |
| 2018 Q4 | 35.92 Million ILS | 0.0% |
| 2018 FY | 35.92 Million ILS | 50.0% |
| 2018 Q1 | 21.23 Million ILS | -11.34% |
| 2017 Q1 | 25.17 Million ILS | -9.21% |
| 2017 Q3 | 25.14 Million ILS | 3.72% |
| 2017 Q4 | 23.94 Million ILS | -4.78% |
| 2017 FY | 23.94 Million ILS | -13.66% |
| 2017 Q2 | 24.24 Million ILS | -3.7% |
| 2016 Q3 | 19.28 Million ILS | 14.78% |
| 2016 FY | 27.73 Million ILS | 119.75% |
| 2016 Q4 | 27.73 Million ILS | 43.83% |
| 2016 Q2 | 16.8 Million ILS | -3.14% |
| 2016 Q1 | 17.34 Million ILS | 37.44% |
| 2015 Q4 | 12.62 Million ILS | -8.49% |
| 2015 Q3 | 13.79 Million ILS | -7.39% |
| 2015 Q1 | 16.39 Million ILS | 520.93% |
| 2015 FY | 12.62 Million ILS | 378.04% |
| 2015 Q2 | 14.89 Million ILS | -9.16% |
| 2014 Q4 | 2.64 Million ILS | -10.9% |
| 2014 Q3 | 2.96 Million ILS | -33.24% |
| 2014 Q2 | 4.43 Million ILS | -16.17% |
| 2014 Q1 | 5.29 Million ILS | -14.1% |
| 2014 FY | 2.64 Million ILS | -57.17% |
| 2013 Q4 | 6.16 Million ILS | -37.92% |
| 2013 FY | 6.16 Million ILS | -57.57% |
| 2013 Q1 | 12.74 Million ILS | -12.26% |
| 2013 Q2 | 11.4 Million ILS | -10.51% |
| 2013 Q3 | 9.92 Million ILS | -12.95% |
| 2012 FY | 14.52 Million ILS | 397.71% |
| 2012 Q2 | 3.63 Million ILS | 0.0% |
| 2012 Q3 | 13.09 Million ILS | 260.43% |
| 2012 Q4 | 14.52 Million ILS | 10.98% |
| 2012 Q1 | 3.63 Million ILS | 397.71% |
| 2011 Q1 | 729.8 Thousand ILS | 0.0% |
| 2011 FY | 2.91 Million ILS | 0.0% |
| 2011 Q2 | 729.8 Thousand ILS | 0.0% |
| 2011 Q3 | 729.8 Thousand ILS | 0.0% |
| 2011 Q4 | 729.8 Thousand ILS | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Theratechnologies Inc. | 77.76 Million USD | -911.475% |
| Harrow Health, Inc. | 311.75 Million USD | -152.318% |
| Dynavax Technologies Corporation | 997.09 Million USD | 21.11% |
| Biofrontera Inc. | 27.93 Million USD | -2716.175% |
| Cronos Group Inc. | 1.13 Billion USD | 30.649% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -5181.77% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -66.983% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1305.948% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -3313.066% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -861.912% |
| Radius Health, Inc. | 1.71 Billion USD | 54.159% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -1376.183% |
| DURECT Corporation | 45.18 Million USD | -1640.72% |
| ProPhase Labs, Inc. | 91.92 Million USD | -755.694% |
| Safety Shot Inc | 12.7 Million USD | -6089.337% |
| Phibro Animal Health Corporation | 982.18 Million USD | 19.912% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -3301.272% |
| Alvotech | 950.09 Million USD | 17.206% |
| Assertio Holdings, Inc. | 286.41 Million USD | -174.638% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 44.171% |
| Rockwell Medical, Inc. | 52.17 Million USD | -1407.703% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -2776.422% |
| Procaps Group S.A. | 460.18 Million USD | -70.934% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -8.008% |
| SCYNEXIS, Inc. | 128.41 Million USD | -512.57% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -566.086% |
| Viatris Inc. | 47.68 Billion USD | 98.35% |
| OptiNose, Inc. | 107.72 Million USD | -630.179% |
| SIGA Technologies, Inc. | 254.83 Million USD | -208.674% |
| Tilray Brands, Inc. | 4.33 Billion USD | 81.856% |
| PetIQ, Inc. | 868.22 Million USD | 9.4% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -2776.422% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 75.807% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -6500.12% |
| Alimera Sciences, Inc. | 153.52 Million USD | -412.372% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 31.198% |
| Silver Spike Investment Corp. | 88.57 Million USD | -788.064% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -13116.547% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -70.994% |
| Journey Medical Corporation | 76.84 Million USD | -923.584% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -2227.55% |
| Alpha Teknova, Inc. | 128.58 Million USD | -511.737% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -2417.729% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -187.398% |
| PainReform Ltd. | 9.93 Million USD | -7821.591% |
| Cosmos Health Inc. | 66.29 Million USD | -1086.526% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -201.239% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -1716.283% |
| Embecta Corp. | 1.21 Billion USD | 35.226% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -9222.047% |
| Talphera, Inc. | 20.39 Million USD | -3756.896% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 50.037% |
| Incannex Healthcare Limited | 17.04 Million USD | -4514.384% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -5837.813% |
| Shineco, Inc. | 84.17 Million USD | -834.45% |
| Procaps Group, S.A. | 460.18 Million USD | -70.934% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 13.026% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -1269.978% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 52.36% |
| Alvotech | 950.09 Million USD | 17.206% |
| Hempacco Co., Inc. | 18.04 Million USD | -4259.644% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -93.671% |
| Bright Green Corporation | 17.4 Million USD | -4419.979% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -282.23% |
| Kamada Ltd. | 351.96 Million USD | -123.489% |
| Indivior PLC | 1.95 Billion USD | 59.686% |
| Evoke Pharma, Inc. | 7.06 Million USD | -11028.371% |
| Flora Growth Corp. | 23.62 Million USD | -3229.442% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -5837.813% |
| Evolus, Inc. | 188.99 Million USD | -316.202% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 38.535% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 48.007% |
| Akanda Corp. | 8.83 Million USD | -8798.355% |